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tigation of Korula et al. (3) in which EST was compared 
with conventional therapy in patients who had survived 
an episode of variceal bleeding. Cumulative survival 
showed no significant difference between the two thera- 
pies. Reassessment of the data after all patients in both 
treatment groups who had had portal-systemic anasto- 
moses were retrospectively censored, i.e., were considered 
to have been lost to follow-up at the time of shunt surgery 
and, therefore, excluded from the survival calculations, 
showed EST to be superior to conventional therapy in 
prolonging life (p < 0.05). This reversal in outcome 
resulted from the fact that portal-systemic shunts, which 
effectively prevented recurrence of hemorrhage, were 
performed in 16 of 57 patients in the conventional ther- 
apy group who bled from varices frequently, compared 
to only 4 of 63 in the EST group who bled infrequently. 
In essence, the use of the shunt in a large fraction of the 
control group tended to show a trend toward improved 
survival compared to the EST group. 
The second study by Warren and his co-workers com- 
pared EST with distal splenorenal shunts (DSRS). They 
found during 2 years of follow-up that recurrence of 
bleeding occurred in 40% of the EST group compared to 
14% of the DSRS group (p < 0.01). Eleven of the 36 
(31%) of the patients who rebled after EST were consid- 
ered failures of therapy and then had DSRS. Ten of the 
11 had prolonged survival which resulted in better cu- 
mulative survival in the EST-DSRS-treated patients 
than in those treated with either EST or DSRS alone. 
Here, the performance of DSRS clearly rescued the pa- 
tients who had failed EST. 
The third investigation by Cello and associates com- 
pared acute, recurrent EST during active variceal hem- 
orrhage with emergency portacaval anastomosis. They 
found survival in the two groups to be similar, but 
pointed out that 7 of the 16 patients (40%) who survived 
the initial admission after EST were considered failures 
of EST therapy and required elective shunt surgery after 
which they enjoyed long-term survival. The authors sug- 
gest that elective shunt surgery be considered for those 
who fail EST. 
All three studies arrived in different ways at a similar 
conclusion: EST is usually effective in preventing vari- 
ceal hemorrhage, but when it isn’t, shunt therapy may 
be lifesaving. Implicit in this reasoning is the knowledge 
that elective shunt surgery has not improved cumulative 
survival over conventional, nonsurgical therapy in any 
of eight published RCTs. Perhaps studies should be 
designed to assess such therapeutic sequences in which 
patients who have recurrent variceal hemorrhage are 
randomized to have shunt surgery, devascularization 
therapy, pharmacologic reduction of portal venous pres- 
sure and/or other therapy. 
Perhaps, no therapy, like no man, is entire unto itself, 
and each type of treatment should be considered to be a 
single cog in the wheel of therapy. Alternatively, these 
reports of shunt rescue may be regarded as artifacts of 
analysis that result from ”cross-over” therapy. 
Cross-over therapy is defined as the use of the “other” 
treatment when the investigational treatment selected 
randomly has failed. Such deviations from protocol rep- 
resent investigational flaws. They are acceptable in hu- 
man studies because one does not expect a physician- 
investigator to persist in administering a therapy that 
has failed, until the ultimate endpoint as is standard 
procedure in animal or laboratory experiments. Conse- 
quently, one may infer unanticipated clues to new ther- 
apeutic sequences, e.g., EST-portacaval anastomosis, 
from such unrandomized investigational misadventures 
that may require further investigations to elucidate. 
Whether shunt rescue is an artifact of analysis or a 
valid phenomenon is not known, but it should at  least 
be considered a therapeutic opportunity. After all, it has 
knocked three times. 
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Elsewhere CORRESPONDENCE 
To the Editor. 
1 found the comments by Dr. I. Herbert Scheinberg on 
zinc therapy of Wilson’s disease in “HEPATOLOGY 
Elsewhere” (1) quite interesting and am moved to make 
two observations. The first is that Dr. Scheinberg has 
worked and published extensively on Wilson’s disease, 
and is currently regarded as one of the leading American 
experts on this disease. Thus, his negative comments on 
the use of zinc in Wilson’s disease are quite likely to be 
taken very seriously by many physicians treating pa- 
tients with Wilson’s disease. 
This likelihood leads me to my second observation, 
namely that Dr. Scheinberg articulates no specific rea- 
sons for his sweeping conclusion that “zinc has no place 
in the treatment of Wilson’s disease, except for those 
who have had a significant, irreversible reaction to both 
penicillamine and Trien.” Dr. Scheinberg makes several 
assertions in support of his position: (i) penicillamine is 
not very toxic, and when it is, Trien can be used effec- 
tively; (ii) a controlled double-blind study of zinc efficacy 
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cannot be done ethically; and (iii) that years of zinc 
administration may reveal it to be toxic. 
The first assertion is arguable, the second, irrelevant 
and the third hypothetical. Even if all the assertions were 
true, they don’t justify Dr. Scheinberg’s sweeping indict- 
ment of zinc therapy. If such statements were accepted, 
therapeutic progress would come to a screeching halt. 
Regarding the first assertion, Dr. Scheinberg’s own 
monograph (2) indicates a 20% initial hypersensitivity 
to penicillamine often requiring corticosteroids, a 10% 
initial neurological worsening and a long list of chronic 
toxicities from penicillamine. In his own words, “We 
make strenuous efforts to overcome any reactions to it 
before considering the use of Trien.” He reports intoler- 
ance in only 2% of patients. Others mention 10% (3), 
which is more in keeping with our own experience. Also, 
a high proportion of our patients have some degree of 
chronic intolerance, such as proteinuria, facial wrinkling, 
loss of taste, thrombocytopenia or poor wound healing. 
The second assertion is irrelevant because a double- 
blind study is not necessary to evaluate maintenance 
anticopper therapy in Wilson’s disease. (No such trial 
was done with Trien, and there is much to be learned 
about its potential toxicity and limits of efficacy.) If the 
trial is properly designed to study previously decoppered 
patients, the intervening variables of urinary copper, 
nonceruloplasmin plasma copper, copper balance and 
oral %opper uptake will show lack of efficacy long before 
the patient is at risk of renewed symptoms from copper 
toxicity. Thus, no ethical issue exists. 
The third assertion, that prolonged zinc therapy will 
produce as yet unknown toxicities is sheer speculation. 
Zinc has a theoretic advantage over penicillamine, in 
that it is a natural body constituent and unlikely to 
provoke an immune reaction even after years of therapy. 
Late immune reactions that produce a variety of syn- 
dromes occur with penicillamine but have not yet been 
seen in 20 patients treated with zinc from 3 to 5 years. 
Finally, if we accept the thesis that once we have an 
efficaceous treatment for a disorder, it is unethical to try 
any other treatment, one of the most important compo- 
nents of medical progress will cease. We have very few 
magic bullets in medicine. We must strive to improve 
treatment in progressive steps that may involve com- 
bined or sequential therapy. The “proof of the pudding” 
in this case will be the extent to which penicillamine is 
used as maintenance therapy of Wilson’s disease by the 
next generation of physicians. I’m betting that it won’t 
be used very much because of its relatively high toxicity, 
which is not to say that it has not been an important 
and life-saving drug. Its time may well have been yester- 
day, and perhaps today, but certainly not tomorrow. 
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